BioSpecifics awaits factory refurbishment:
This article was originally published in Clinica
BioSpecifics, a Lynbrook, New York company producing collagenase for use in UK woundcare, orthopaedics and endoscopy company Smith & Nephew's Collagenase Santyl, has reported that normal production will be resumed when its newly refurbished facility gains FDA approval. The company, which is also engaged in a clinical trial for an injectable treatment for Peyronie's and Dupuytren's diseases, reported $2.8 million in revenues in the first quarter, compared with $1.4 million in the same period last year. It made a profit of $175,000 compared with a loss of $600,000.